The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor
Podurgiel S, Nunes E, Yohn S, Barber J, Thompson A, Milligan M, Lee C, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller C, Correa M, Salamone J. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 2013, 250: 507-519. PMID: 23867769, DOI: 10.1016/j.neuroscience.2013.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAnimalsCatalepsyData Interpretation, StatisticalDisease Models, AnimalDose-Response Relationship, DrugJawMaleMiceMice, KnockoutMotor ActivityMovementParkinsonian DisordersProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleyReceptor, Adenosine A2ATetrabenazineTremorVesicular Monoamine Transport ProteinsXanthinesConceptsTremulous jaw movementsVentrolateral neostriatumC-fos expressionMSX-3Receptor transmissionAdenosine A2A antagonist MSX-3A2A receptor knockout miceParkinsonian tremorC-Fos-positive cellsAbility of tetrabenazineParkinsonian side effectsVesicular monoamine storageJaw movementsReceptor knockout miceAdenosine A2A receptorsOral tremorWild-type controlsPharmacological antagonismStriatal dopamineLocomotor suppressionMotor effectsCD1 miceRodent modelsKnockout miceSide effects